Skip to main content
U.S. flag

An official website of the United States government

News Releases

NIH to assess and expand COVID-19 testing for underserved communities

The National Institutes of Health has awarded nearly $234 million to improve COVID-19 testing for underserved and vulnerable populations. A part of the Rapid Acceleration of Diagnostics (RADx) initiative, the RADx Underserved Populations (RADx-UP) program will support 32 institutions across the United States and will focus on populations disproportionately affected by the pandemic. These groups include African Americans, American Indians/Alaskan Natives, Latinos/Latinas, Native Hawaiians, older adults, pregnant women, and those who are homeless or incarcerated.

A row of abstract human figures made of white wood, with a single red figure that stands out, representing individuality and being different.“It is critical that all Americans have access to rapid, accurate diagnostics for COVID-19, especially underserved and vulnerable populations who are bearing the brunt of this disease,” said NIH Director Francis S. Collins, M.D., Ph.D. “The RADx-UP program will help us better understand and alleviate the barriers to testing for those most vulnerable and reduce the burden of this disease.”

The program aims to understand COVID-19 testing patterns better among underserved and vulnerable populations; strengthen the data on disparities in infection rates, disease progression, and outcomes; and develop strategies to reduce these disparities in COVID-19 testing. To accomplish these goals in rapid fashion, the RADx-UP program is supporting projects with established community partnerships that can use their existing research infrastructures to swiftly implement strategies and interventions to increase access and uptake of COVID-19 testing among underserved and vulnerable populations.

The RADx-UP program has three primary components supported by these NIH grants to increase availability, accessibility, and acceptance of testing among underserved and vulnerable populations:

  1. A collaborative clinical research network of existing large-scale programs that have adequate capacity, infrastructure, and relationships with underserved communities. These are the first set of awards; NIH expects to issue a second group of awards later this year, pending availability of funds, to programs with established community engagement components, which will also form part of the collaborative network. Together these programs will develop and implement interventions to increase access and uptake of COVID-19 testing.
  2. Research on the social, ethical, and behavioral implications of these health disparities to inform the development and evaluation of testing programs. These projects will focus on assessing how ethical, historical, health care, social, economic, and contextual factors, as well as cultural beliefs and attitudes, expectations, and preferences influence the ability and willingness to be tested.
  3. A coordination and data collection center at Duke University, Durham, North Carolina, providing overarching support and guidance on administrative operations and logistics, facilitating effective use of COVID-19 testing technologies, supporting community and health system engagement, and providing overall infrastructure for data collection, integration, and sharing.

“Long-term community engagement efforts established by these researchers and programs provide an essential mechanism for discovering the factors that lead to COVID-19 related disparities,” said Eliseo J. Pérez-Stable, M.D., director of the National Institute on Minority Health and Health Disparities. “These existing partnerships will serve as the foundation for swift implementation of interventions to promote greater health equity.”

In the coming months, the RADx-UP program will award additional funding, pending availability of funds, to address the evolving needs of the pandemic response; integrate new scientific and/or technologic advances such as vaccines, novel therapeutics, and new testing approaches; and expand the studies and/or populations being reached.

About the Rapid Acceleration of Diagnostics (RADxSM) initiative: The RADx initiative was launched on April 29, 2020, to speed innovation in the development, commercialization, and implementation of technologies for COVID-19 testing. The initiative has four programs: RADx Tech, RADx Advanced Technology Platforms, RADx Underserved Populations, and RADx Radical. It leverages the existing NIH Point-of-Care Technology Research Network. The RADx initiative partners with federal agencies, including the Office of the Assistant Secretary of Health, Department of Defense, the Biomedical Advanced Research and Development Authority, and U.S. Food and Drug Administration. Learn more about the RADx initiative and its programs:

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

An official website of the National Institutes of Health